Clever Culture Systems (CC5) investor relations material

Market challenges and needs

• Manual reading of millions of culture plates in pharmaceutical manufacturing leads to costly errors and inefficiencies, with failed results risking up to US $1bn in lost revenue and patient safety concerns.

• Regulatory scrutiny has increased by 116%, intensifying compliance demands for drug manufacturers.

• Up to 98% of plates show no growth but still require dual analyst verification, wasting significant resources.

Solution and technology

• APAS Independence uses AI and machine learning to automate culture plate assessment, providing faster and more accurate results than manual microbiologist review.

• The system integrates easily into existing workflows, offering automatic data trails, audit reports, and plug-and-play operation.

• Over 90% of plates can be automatically cleared for batch release, with only 2-10% requiring manual review.

Revenue model and market opportunity

• Each APAS Independence sale can generate up to $1.2M in revenue, combining upfront Capex and recurring ARR streams.

• The total addressable pharmaceutical market is valued at $2.8B, with a $230M annual SaaS opportunity and market CAGR above 8%.

• Current sales include 22 instruments and 10 customers, with a qualified pipeline representing 180 additional instruments.